GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Gross Profit

Medexus Pharmaceuticals (TSX:MDP) Gross Profit : C$74.5 Mil (TTM As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Gross Profit?

Medexus Pharmaceuticals's gross profit for the three months ended in Sep. 2024 was C$19.1 Mil. Medexus Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was C$74.5 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Medexus Pharmaceuticals's gross profit for the three months ended in Sep. 2024 was C$19.1 Mil. Medexus Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was C$35.6 Mil. Therefore, Medexus Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2024 was 53.70%.

Medexus Pharmaceuticals had a gross margin of 53.70% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Medexus Pharmaceuticals was 68.63%. The lowest was 49.45%. And the median was 55.40%.

Warning Sign:

Medexus Pharmaceuticals Inc gross margin has been in long-term decline. The average rate of decline per year is -2%.


Medexus Pharmaceuticals Gross Profit Historical Data

The historical data trend for Medexus Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Gross Profit Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.47 52.80 48.02 82.15 80.56

Medexus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.03 17.03 18.01 20.33 19.14

Competitive Comparison of Medexus Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Gross Profit falls into.



Medexus Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Medexus Pharmaceuticals's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=153.03 - 72.472
=80.6

Medexus Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=35.63 - 16.495
=19.1

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$74.5 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Medexus Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=19.1 / 35.63
=53.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Medexus Pharmaceuticals  (TSX:MDP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Medexus Pharmaceuticals had a gross margin of 53.70% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Medexus Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Executives
Brendon Buschman Senior Officer
Benoit Gravel Director
Stephen William Nelson Director
Kenneth D'entremont Director, Senior Officer
Mike Mueller Director
Marcel Pascal Konrad Senior Officer
Brian Peters Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin Senior Officer
Michael Pine Senior Officer
Glenn Tate Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle Senior Officer
Benoît Hébert Senior Officer